KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Acquisitions (2016 - 2022)

Historic Acquisitions for Eli Lilly (LLY) over the last 12 years, with Q4 2022 value amounting to $327.2 million.

  • Eli Lilly's Acquisitions changed N/A to $327.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $327.2 million, marking a year-over-year decrease of 5622.16%. This contributed to the annual value of $327.2 million for FY2022, which is 5622.16% down from last year.
  • Per Eli Lilly's latest filing, its Acquisitions stood at $327.2 million for Q4 2022.
  • Eli Lilly's Acquisitions' 5-year high stood at $6.9 billion during Q1 2019, with a 5-year trough of $327.2 million in Q4 2022.
  • Over the past 4 years, Eli Lilly's median Acquisitions value was $798.3 million (recorded in 2020), while the average stood at $2.2 billion.
  • As far as peak fluctuations go, Eli Lilly's Acquisitions plummeted by 8772.28% in 2020, and later plummeted by 1199.81% in 2021.
  • Quarter analysis of 4 years shows Eli Lilly's Acquisitions stood at $6.9 billion in 2019, then plummeted by 87.72% to $849.3 million in 2020, then dropped by 12.0% to $747.4 million in 2021, then crashed by 56.22% to $327.2 million in 2022.
  • Its last three reported values are $327.2 million in Q4 2022, $747.4 million for Q1 2021, and $849.3 million during Q1 2020.